ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0718

Incidence of Venous Thromboembolism in Patients with ANCA-Associated Vasculitides – a Nationwide Registry-Based Study from Sweden

Hanna Lindberg1, Klytaimnistra Voudouri1, Lars Lindhagen1, Maria K Svensson2, Ann Knight1 and Johanna Dahlqvist3, 1Uppsala University, Uppsala, Sweden, 2Uppsala University, Uppsala, 3Uppsala University Hospital, Uppsala, Sweden

Meeting: ACR Convergence 2025

Keywords: ANCA associated vasculitis, Cardiovascular, Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0711–0730) Vasculitis – ANCA-Associated Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides (AAV) are rare yet severe autoimmune diseases. Previous studies have indicated that patients with AAV have an increased risk of venous thromboembolism (VTE) including deep vein thrombosis (DVT) and pulmonary embolism (PE). However, it remains unclear whether the risk is increased equally in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), and across both sexes. Therefore, the aim of this study was to assess the risk and timing of VTE events in men and women with GPA and MPA, respectively.

Methods: In a nationwide case-control study, all patients >18 years old with incident GPA or MPA between January 1, 2005, and December 31, 2020, where identified from the National Patient Registers (NPRs) in Sweden. For each patient, five population controls matched for sex and age were selected from the Statistics Sweden Register of Total Population. Primary outcomes were DVT and PE following av AAV diagnosis, identified in the NPRs using ICD codes. Hazard ratios (HRs) of the primary outcomes were calculated using Cox models stratified for AAV subtype and sex, with complete follow-up time or censored after one year and 90 days follow-up post AAV diagnosis, respectively.

Results: In total, 4317 patients (3159 with GPA and 1158 with MPA and 21582 population controls were included in the study. There was no significant difference in risk of VTE between patients with GPA and MPA. Both GPA and MPA were associated with a more than three-fold increased risk of DVT and PE during the entire follow-up time, compared to population controls. This risk was increased to more than 11-fold when follow-up time was censored after one year and more than 20-fold when censored after 90 days (HR (95% confidence interval); HR 21.30 (10.67-42.52)) and PE (HR 22.84 (13.04-40.02)). In sex-stratified analyses, men with GPA and MPA, respectively, exhibited a more than four-fold increased risk of DVT (HR 4.15 (3.07-5.61); 3.49 (2.01-6.06)) and PE (HR 4.68 (3.61-6.06); HR 4.01 (2.47-6.51)). Similarly, women with GPA and MPA, respectively, showed a more than three-fold increased risk of DVT (HR 3.22 (2.28-4.55); HR 4.51 (2.56-7.92)) and PE (HR 3.24 (2.43-4.31); HR 3.54 (2.30- 5.45)). Adjusting for kidney disease had only modest effects on HRs across all comparisons.

Conclusion: Both patients with GPA and MPA exhibit an increased risk of DVT and PE following diagnosis of AAV. Our study did not reveal any significant sex differences in VTE among patients with AAV. This study highlights the importance of being aware of the risk for thromboembolic events, in particular during the first year following an AAV diagnosis.


Disclosures: H. Lindberg: None; K. Voudouri: None; L. Lindhagen: None; M. K Svensson: Amgen, 6, AstraZeneca, 6, Boehringer-Ingelheim, 6, CSL Vifor Pharma, 6, GlaxoSmithKlein(GSK), 6, NovoNordisk, 6; A. Knight: None; J. Dahlqvist: CSL Vifor, 6.

To cite this abstract in AMA style:

Lindberg H, Voudouri K, Lindhagen L, K Svensson M, Knight A, Dahlqvist J. Incidence of Venous Thromboembolism in Patients with ANCA-Associated Vasculitides – a Nationwide Registry-Based Study from Sweden [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/incidence-of-venous-thromboembolism-in-patients-with-anca-associated-vasculitides-a-nationwide-registry-based-study-from-sweden/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/incidence-of-venous-thromboembolism-in-patients-with-anca-associated-vasculitides-a-nationwide-registry-based-study-from-sweden/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology